2VAZIRI N D, RODRIGUEZ-ITURBE B. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension [J]. Nat Clin Pract Nephrol, 2006,2 : 582 - 593.
3STEVENS P E, LEVIN A. Evaluation and manage- ment of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical prac- tice guideline[J]. Ann Intern Med, 2013,158:825 - 830.
4TSIOUFIS C, DIMITRIADIS K, CHATZIS D, et al. Relation of microalbuminuria to adiponectin and aug-mented C-reactive protein levels in men with essential hypertension[J]. Am J Cardiol, 2005,96 : 946 - 951.
5COTTONE S, MULE G, NARDI E,et al. Microalbu- minuria and early endothelial activation in essential hypertension[J]. J Hum Hypertens, 2007,21: 167- 172.
6HIDA K, WADA J, EGUCHI J,et al. Visceral adi- pose tissue-derived serine protease inhibitor., a unique insulin-sensitizing adipocytokine in obesity [J]. Proc Natl Acad Sci U S A,2005,102:10610-10615.
7JUNGC H, LEE W J, HWANG J Y,et al. Vaspin increases nitric oxide bioavailability through the re- duction of asymmetric dimethylarginine in vascular en- dothelial cells[J]. PLoS One, 2012,7 : e52346.
8LI H L, PENG W H, CUI S T, et al. Vaspin plasma concentrations and mRNA expressions in patients with stable and unstable angina pectoris [J]. Clin Chem Lab Med,2011,49:1547-1554.
9KAWANO K1, HIRASHIMA T, MORI S, et al. Spontaneous long-term hyperglycemic rat with diabet- ic complications. Otsuka Long-Evans Tokushima Fat- ty (OLETF) strain[J]. Diabetes, 1992, 41:1422 - 1428.
10KADOGLOU N P, GKONTOPOULOS A, KAPE- LOUZOU A,et al. Serum levels of vaspin and visfatin in patients with coronary artery disease-Kozani study E Jl. Clin Chim Acta, 2011,412 : 48 - 52.
